Federal Register #2026-09715

Preliminary Results and Partial Rescission of Antidumping Duty Administrative Review for Glycine from India

This notice from the International Trade Administration (ITA), U.S. Department of Commerce, announces preliminary results of the antidumping duty administrative review for glycine imported from India. - Government Buyer: - International Trade Administration (ITA), U.S. Department of Commerce - Key Companies (OEMs/Exporters): - Medilane Healthcare Private Limited - Mulji Mehta Enterprises - 27 other companies (including Avid Organics Private Limited, Bajaj Healthcare Limited, Paras Intermediates Private Limited) had their reviews rescinded - Products/Services: - Glycine (no specific part numbers or quantities; relates to trade enforcement, not procurement) - Notable Requirements: - Preliminary weighted-average dumping margin of 57.17% for Medilane Healthcare Private Limited and Mulji Mehta Enterprises - Review period covers one year - Procedures for assessment rates and cash deposit requirements outlined - Opportunity for interested parties to comment on the preliminary results - This is a trade enforcement action, not a procurement or purchase request.

Description

The U.S. Department of Commerce preliminarily determines that producers and/or exporters subject to this administrative review made sales of glycine from India at less than normal value during the period of review from June 1, 2024, through May 31, 2025. The review is rescinded in part with respect to 27 companies that withdrew their requests for review. Interested parties are invited to comment on these preliminary results. The review involves antidumping duties and assessment rates for the subject merchandise.

View original listing